CDC Awards $1,000,000 Single-Source Grant to HJF Medical Research International, Kenya
More From This Agency
- HHS Notices Prospective Exclusive Patent License for Mifepristone Analogs to Treat Hypercortisolism-Related Insulin Resistance September 2, 2026
- HRSA Seeks Public Comment on Proposed Faculty Loan Repayment Program Data Collection (OMB No. 0906-0082-Revision) August 21, 2026
- HHS Seeks 3‑Year Generic Clearance to Collect TEFCA Feedback August 17, 2026
- FDA Determines ANSAID (Flurbiprofen) Tablets Were Not Withdrawn for Safety or Effectiveness August 17, 2026
- NCI Offers License for CRISPR-Engineered MC38 B2m‑KO Murine Colon Cancer Cell Line August 16, 2026
Plain-English Summary
The Centers for Disease Control and Prevention issued a notice announcing a single-source grant of about $1 million to HJF Medical Research International, Inc., Kenya for fiscal year 2026. The award is contingent on the availability of federal funds. Funding for the second through fifth years will be set only if the program continues and funds remain. The notice serves as the official public record of the award.
Current Status
This is a notice announcing a grant award, not a rulemaking; it is a final, informational publication in the Federal Register.
What This Means
The abstract states that CDC is providing a one‑time award of roughly $1 million to the Kenyan organization for FY 2026, meaning the agency has selected HJF Medical Research International as the sole recipient without a competitive bidding process. The grant will be disbursed only if the appropriated funds are still available when the award is executed. For years two through five, the agency will evaluate the program and allocate additional money only if the project is continued and funds are still on hand. The language "subject to the availability of funds" indicates that the award could be reduced or delayed if budget constraints arise. The continuation amounts are not fixed in this notice and will be determined later based on program performance and funding status.
Who Is Affected
The primary beneficiary is HJF Medical Research International, a Kenyan research entity that will receive federal money to conduct health‑related work. U.S. public‑health interests may be impacted, as CDC’s investment supports global disease surveillance or research that could affect U.S. health security. No U.S. private industry or domestic agencies are directly receiving funds, though collaborators in Kenya or international partners may engage with the grant activities.
Background
The notice appears because CDC is exercising its statutory authority to fund international health research under the Department of Health and Human Services’ global health mandate. Single‑source awards are permitted when the agency determines that only one organization possesses the necessary expertise or capacity. The FY 2026 budget allocation for overseas health initiatives likely prompted the agency to formalize the award at the start of the fiscal year. The abstract does not reference a prior solicitation, suggesting the grant was pre‑identified as essential for a specific research program.
Arguments For
Proponents argue that the grant enables critical medical research in Kenya that can improve disease detection and response, aligning with CDC’s mission to protect public health globally. The funding also strengthens U.S.–Kenya health partnerships and may yield data or interventions that benefit both countries.
Arguments Against
The abstract provides no indication of controversy; however, critics could note that a single‑source award bypasses competitive procurement, potentially limiting transparency and cost‑effectiveness. If funds become unavailable, the project could be disrupted, raising concerns about reliance on uncertain budget allocations.
Economic Considerations
The notice does not include an official cost estimate, so any analysis is tentative. The $1 million grant represents a modest infusion of U.S. federal resources into Kenyan health research, likely generating local employment and procurement for laboratory supplies. Continuation funding could increase total outlays over five years if the program is extended, but exact amounts remain undetermined. Potential economic benefits include capacity building and possible downstream health savings, though these are speculative without program metrics.
Sections beyond the plain-English summary are AI-synthesized analysis based on the sourced Federal Register filing, read, edited where needed, and approved by a human editor before publication. Full methodology: Editorial & Methodology.
← All Records